(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 February 2014 (27.02.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/031822 A1

(51) International Patent Classification:
*C07K 16/12* (2006.01) *A61K 39/40* (2006.01)

(21) International Application Number:
PCT/US2013/056124

(22) International Filing Date:
22 August 2013 (22.08.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/693,001 24 August 2012 (24.08.2012) US
1356743 9 July 2013 (09.07.2013) FR

(71) Applicant: **SANOFI** [FR/FR]; Rue La Boetie, F-75008 Paris (FR).

(72) Inventors: **REY, Astrid**; c/o Sanofi, Rue La Boetie, F-75008 Paris (FR). **CANTALLOUBE, Cathy**; c/o Sanofi, Rue La Boetie, F-75008 Paris (FR). **LI, Meng**; c/o Sanofi, 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, NJ 08807 (US). **TANG, Lei**; c/o Sanofi, 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, NJ 08807 (US). **VLOCK, Daniel**; c/o Alopexx Pharmaceuticals, LLC, 100 Main Street, Suite 110, Concord, MA 01742 (US).

(74) Agents: **VELEMA, James, H.** et al.; Lathrop & Gage LLP, 28 State Street, Boston, MA 02109 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


**Published**:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: ANTI-POLY-N-ACETYL GLUCOSAMINE (PNAG) MONOCLONAL ANTIBODY AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF PNAG EXPRESSING BACTERIAL INFECTION

*Figure 1*




(57) Abstract: Provided are methods for the treatment or prevention of microbial infections (e.g., bacterial infection) in which the underlying pathology involves a PNAG-expressing microbe (e.g., PNAG-expressing bacteria). The methods of the invention generally involve administering to the subject an effective amount of an antibody that specifically binds to PNAG. Such methods are particularly useful for the treatment of nosocomial staphylococcus (e.g., *S. epidermidis* and *S. aureus*) infections.

WO 2014/031822 A1